reviewThe Lancet OncologyOct 31, 2007Closed access

Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia

JFJane F. Apperley

Hammersmith Hospital

Indexed incrossref

Abstract

No abstract available for this paper.

Citation impact

635
total citations
FWCI
24.79
Percentile
100%
References
90
Citations per year

Authors

1

Topics & keywords

Topics
Keywords
  • Imatinib
  • Chronic myeloid leukaemia
  • Medicine
  • Tyrosine kinase
  • Myeloid leukemia
  • Drug resistance
  • Tyrosine-kinase inhibitor
  • Disease
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.